This record was last updated September 23, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.
Protocol Amendment History
10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-04-29; most recent amendment 2025-09-22.
Status change: Not Yet Recruiting → Recruiting2024-09-30